You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for CGP 35348
CGP 35348 is a selective, brain penetrant GABAB receptor antagonist (IC50 = 34 μM as measured in rat cortical membranes). Has higher affinity for postsynaptic versus presynaptic receptors.
Sold with the permission of Novartis Pharma AG
Technical Data for CGP 35348
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for CGP 35348
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for CGP 35348
The following data is based on the product molecular weight 225.22. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.44 mL||22.2 mL||44.4 mL|
|5 mM||0.89 mL||4.44 mL||8.88 mL|
|10 mM||0.44 mL||2.22 mL||4.44 mL|
|50 mM||0.09 mL||0.44 mL||0.89 mL|
References for CGP 35348
References are publications that support the biological activity of the product.
Hao et al (1994) Intrathecal γ-aminobutyric acidB (GABAB) receptor antagonist CGP 35348 induces hypersensitisation to mechanical stimuli in the rat. Neurosci.Lett. 182 299 PMID: 7715832
Olpe et al (1990) CGP 35348: a centrally active blocker of GABAB receptors. Eur.J.Pharmacol. 187 27 PMID: 2176979
Staubli et al (1999) GABAB receptor antagonism: facilitatory effects on memory parallel those on LTP induced by TBS but not HFS. J.Neurosci. 19 4609 PMID: 10341258
Sutor and Luhmann (1998) Involvement of GABAB receptors in convulsant-induced epileptiform activity in rat neocortex in vitro. Eur.J.Neurosci. 10 3417 PMID: 9824455
If you know of a relevant reference for CGP 35348, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: CGP 35348, CGP 35348 supplier, Brain, penetrant, selective, GABAB, antagonists, Receptors, CGP35348, 1245, Tocris Bioscience
11 Citations for CGP 35348
Citations are publications that use Tocris products. Selected citations for CGP 35348 include:
Wood et al (2000) The human GABA(B1b) and GABA(B2) heterodimeric recombinant receptor shows low sensitivity to phaclofen and saclofen. Nat Commun 131 1050 PMID: 11082110
Lecrux et al (2011) Pyramidal neurons are "neurogenic hubs" in the neurovascular coupling response to whisker stimulation. J Neurosci 31 9836 PMID: 21734275
Gantz et al (2013) Spontaneous inhibitory synaptic currents mediated by a G protein-coupled receptor. Cell Metab 78 807 PMID: 23764286
Gantz et al (2011) Loss of Mecp2 in substantia nigra DA neurons compromises the nigrostriatal pathway. J Neurosci 31 12629 PMID: 21880923
Zhao et al (2018) Soluble Aβ Oligomers Impair Dipolar Heterodendritic Plasticity by Activation of mGluR in the Hippocampal CA1 Region. iScience 6 138 PMID: 30240608
Aubdool et al (2014) TRPA1 is essential for the vascular response to environmental cold exposure. Neuron 5 5732 PMID: 25501034
Milenković et al (2007) Development of chloride-mediated inhibition in neurons of the anteroventral cochlear nucleus of gerbil (Meriones unguiculatus). J Neurophysiol 98 1634 PMID: 17596413
Huang et al (2015) The in vitro generation of lung and airway progenitor cells from human pluripotent stem cells. Br J Pharmacol 10 413 PMID: 25654758
Xia et al (2014) Regulation of action potential waveforms by axonal GABAA receptors in cortical pyramidal neurons. PLoS One 9 e100968 PMID: 24971996
Gaier et al (2010) Haploinsufficiency in peptidylglycine alpha-amidating monooxygenase leads to altered synaptic transmission in the amygdala and impaired emotional responses. J Neurosci 30 13656 PMID: 20943906
Vashchinkina et al (2014) Neurosteroid Agonist at GABAA receptor induces persistent neuroplasticity in VTA DA neurons. Neuropsychopharmacology 39 727 PMID: 24077066
Do you know of a great paper that uses CGP 35348 from Tocris? Please let us know.
Reviews for CGP 35348
There are currently no reviews for this product. Be the first to review CGP 35348 and earn rewards!
Have you used CGP 35348?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
GABA Receptors Scientific Review
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.